Incyte Q2 Revenue Surges 38% to $1.67B, Raises 2026 Guidance on Broad Product Strength
INCY sits 70% above its 52-week low of $69.695.
Summary
Incyte reported Q2 2026 revenue of $1.67 billion, up 38% year-over-year, and raised full-year 2026 guidance on broad-based product growth and pipeline progress.
Key Events · Earnings and Guidance · INCY
-
Q2 Revenue Hits $1.67B
Total revenue grew 38% YoY to $1.67 billion, with total net sales up 40% to $1.49 billion. Jakafi/Jakafi XR net sales rose 7% to $817 million, Opzelura net sales surged 173% to $450 million (including a $246 million one-time CMS benefit), and the hematology/oncology portfolio jumped 69% to $222 million.
-
2026 Guidance Raised Across Board
Full-year total net sales guidance raised to $5.13-$5.26 billion (from $4.77-$4.94 billion). Opzelura net sales now seen at $1.05-$1.10 billion (from $750-$790 million), and hematology/oncology net sales at $860-$890 million (from $800-$880 million). Total GAAP R&D and SG&A expenses raised to $4.915-$4.995 billion, reflecting the Vega Therapeutics acquisition and incremental R&D investment.
-
Cash Position Strengthens to $4.5B
Cash, cash equivalents and marketable securities totaled $4.5 billion as of June 30, 2026, up from $3.6 billion at year-end 2025, providing ample liquidity for pipeline investment and business development.
-
Pipeline Progress and Upcoming Catalysts
Ten clinical data readouts expected in H2 2026, including four registrational trials. Key updates include Phase 3 data for povorcitinib in prurigo nodularis and ruxolitinib cream in hidradenitis suppurativa, plus multiple presentations at ESMO 2026.
Analysis · INCY · Industrial Applications And Services
A standout quarter saw total revenue jump 38% to $1.67 billion, fueled by robust demand across the entire commercial portfolio. Jakafi/Jakafi XR net sales grew 7% to $817 million, while Opzelura net sales more than doubled to $450 million, boosted by a one-time $246 million CMS settlement benefit. The hematology and oncology franchise surged 69% to $222 million, reflecting accelerating uptake of newer products like Niktimvo, Monjuvi, and Zynyz. Management raised full-year 2026 guidance across all key metrics, now expecting total net sales of $5.13-$5.26 billion, up from $4.77-$4.94 billion. The raised expense guidance incorporates the $1.25 billion Vega Therapeutics acquisition, adding a late-stage von Willebrand disease asset. With $4.5 billion in cash and ten data readouts expected in the second half, Incyte is well-capitalized to fund its pipeline while delivering top-line growth.
At the time of this filing, INCY was trading at $118.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $23.7B. The 52-week trading range was $69.70 to $120.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.